GSK3B and hepatocellular carcinoma: The inhibition of glycolysis mediated by enhanced AMPK/mTOR signaling pathway signaling inhibits the activity of glycogen synthase kinase-3 beta (GSK-3β), which can suppress the acquisition of the malignant hepatocellular carcinoma (HCC) phenotype (Fang et al., 2019).